- Home
- WD vs KNSA Comparison
WD vs KNSA Comparison
Compare WD & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WD
- KNSA
- Stock Information
- Founded
- WD 1937
- KNSA 2015
- Country
- WD United States
- KNSA United Kingdom
- Employees
- WD N/A
- KNSA N/A
- Industry
- WD Finance: Consumer Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- WD Finance
- KNSA Health Care
- Exchange
- WD Nasdaq
- KNSA Nasdaq
- Market Cap
- WD 2.9B
- KNSA 2.6B
- IPO Year
- WD 2010
- KNSA 2018
- Fundamental
- Price
- WD $80.49
- KNSA $38.30
- Analyst Decision
- WD Buy
- KNSA Strong Buy
- Analyst Count
- WD 1
- KNSA 7
- Target Price
- WD $95.00
- KNSA $44.00
- AVG Volume (30 Days)
- WD 232.4K
- KNSA 403.5K
- Earning Date
- WD 11-06-2025
- KNSA 10-28-2025
- Dividend Yield
- WD 3.30%
- KNSA N/A
- EPS Growth
- WD 25.06
- KNSA N/A
- EPS
- WD 3.24
- KNSA 0.07
- Revenue
- WD $1,111,017,000.00
- KNSA $529,332,000.00
- Revenue This Year
- WD $18.16
- KNSA $37.21
- Revenue Next Year
- WD $5.63
- KNSA $12.07
- P/E Ratio
- WD $25.08
- KNSA $577.26
- Revenue Growth
- WD 15.06
- KNSA 56.18
- 52 Week Low
- WD $64.48
- KNSA $17.82
- 52 Week High
- WD $118.19
- KNSA $39.12
- Technical
- Relative Strength Index (RSI)
- WD 40.95
- KNSA 63.72
- Support Level
- WD $81.73
- KNSA $37.35
- Resistance Level
- WD $86.38
- KNSA $38.83
- Average True Range (ATR)
- WD 2.13
- KNSA 0.97
- MACD
- WD -0.63
- KNSA 0.03
- Stochastic Oscillator
- WD 2.24
- KNSA 76.50
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.